Allogene Therapeutics ALLO Business Segments — Supporting external spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept allo:SupportingExternalSpendExpense.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's business segments — supporting external spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's business segments — supporting external spend?
- Allogene Therapeutics (ALLO) reported business segments — supporting external spend of $4.37M in Q1 2026.
- How has Allogene Therapeutics's business segments — supporting external spend changed year-over-year?
- Allogene Therapeutics's business segments — supporting external spend decreased by 25.2% year-over-year, from $5.85M to $4.37M.
- What is the long-term trend for Allogene Therapeutics's business segments — supporting external spend?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — supporting external spend has grown at a -30.8% compound annual growth rate (CAGR), from $43.25M to $20.7M.
- What does business segments — supporting external spend mean?
- This metric encompasses payments to third-party vendors, contract research organizations, and consultants that provide essential support for clinical and operational activities. It reflects the company's reliance on external partnerships to execute its development pipeline. Fluctuations in this metric highlight the company's outsourcing strategy and variable cost management.